Trial · NCT00759408
The Role of Endothelin in Pulmonary Hypertension
NCT00759408, Phase 2, Completed, Brigham and Women's Hospital; results first posted 2018-10-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Endothelin in Pulmonary Hypertension. Trials, record NCT00759408. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00759408
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Endothelin in Pulmonary Hypertension
- NCT number
- NCT00759408
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Pulmonary Hypertension
- Interventions
- BQ-123
- First posted
- 2008-09-25
- Last updated
- 2018-11-27
- Results first posted
- 2018-10-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pulmonary Vascular Resistance (PVR) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | PVR will be measured at these 5 time points: 1) Baseline, 2) Hypoxia induced and maintained for 15 min post-baseline at which time the measurement is taken again, 3) Baseline oxygen saturation (Normoxia) reestablished 15 min post-hypoxia period, at which time the measurement is taken again 4) Normoxia measurement taken after BQ-123 administered for 60 min after time point 3, 5) Hypoxia induced and maintained for 15 min after BQ-123 normoxia period, at which time the measurement is taken again. |
| Secondary | Systemic Vascular Resistance (SVR) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | SVR will be measured at these 5 time points: 1) Baseline, 2) Hypoxia induced and maintained for 15 min post-baseline at which time the measurement is taken again, 3) Baseline oxygen saturation (Normoxia) reestablished 15 min post-hypoxia period, at which time the measurement is taken again 4) Normoxia measurement taken after BQ-123 administered for 60 min after time point 3, 5) Hypoxia induced and maintained for 15 min after BQ-123 normoxia period, at which time the measurement is taken again. |
| Secondary | Mean Pulmonary Artery Pressure (PAP) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | PAP will be measured at these 5 time points: 1) Baseline, 2) Hypoxia induced and maintained for 15 min post-baseline at which time the measurement is taken again, 3) Baseline oxygen saturation (Normoxia) reestablished 15 min post-hypoxia period, at which time the measurement is taken again 4) Normoxia measurement taken after BQ-123 administered for 60 min after time point 3, 5) Hypoxia induced and maintained for 15 min after BQ-123 normoxia period, at which time the measurement is taken again. |
| Secondary | Cardiac Output (CO) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | CO will be measured at these 5 time points: 1) Baseline, 2) Hypoxia induced and maintained for 15 min post-baseline at which time the measurement is taken again, 3) Baseline oxygen saturation (Normoxia) reestablished 15 min post-hypoxia period, at which time the measurement is taken again 4) Normoxia measurement taken after BQ-123 administered for 60 min after time point 3, 5) Hypoxia induced and maintained for 15 min after BQ-123 normoxia period, at which time the measurement is taken again. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pulmonary Vascular Resistance (PVR) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | Only 19 healthy volunteers completed the study. The study was closed before the 19 patients with established pulmonary hypertension could have data collected. | dyn*sec/cm^5 | MEAN |
| SECONDARY | Systemic Vascular Resistance (SVR) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | Only 19 healthy volunteers completed the study. The study was closed before the 19 patients with established pulmonary hypertension could have data collected. | dyn*sec/cm^5 | MEAN |
| SECONDARY | Mean Pulmonary Artery Pressure (PAP) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | Only 19 healthy volunteers completed the study. The study was closed before the 19 patients with established pulmonary hypertension could have data collected. | mmHg | MEAN |
| SECONDARY | Cardiac Output (CO) | Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description) | Only 19 healthy volunteers completed the study. The study was closed before the 19 patients with established pulmonary hypertension could have data collected. | l/min | MEAN |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pulmonary Vascular Resistance (PVR) | BQ-123 | Baseline | 64 | Standard Error 5 | dyn*sec/cm^5 |
| Pulmonary Vascular Resistance (PVR) | BQ-123 | Time 2: Hypoxia | 119 | Standard Error 10 | dyn*sec/cm^5 |
| Pulmonary Vascular Resistance (PVR) | BQ-123 | Time 3: Normoxia | 67 | Standard Error 5 | dyn*sec/cm^5 |
| Pulmonary Vascular Resistance (PVR) | BQ-123 | Time 4: Normoxia/BQ-123 | 46 | Standard Error 5 | dyn*sec/cm^5 |
| Pulmonary Vascular Resistance (PVR) | BQ-123 | Time 5: Hypoxia/BQ-123 | 85 | Standard Error 9 | dyn*sec/cm^5 |
| Systemic Vascular Resistance (SVR) | BQ-123 | Baseline | 1368 | Standard Error 52 | dyn*sec/cm^5 |
| Systemic Vascular Resistance (SVR) | BQ-123 | Time 2: Hypoxia | 1050 | Standard Error 57 | dyn*sec/cm^5 |
| Systemic Vascular Resistance (SVR) | BQ-123 | Time 3: Normoxia | 1351 | Standard Error 44 | dyn*sec/cm^5 |
| Systemic Vascular Resistance (SVR) | BQ-123 | Time 4: Normoxia/BQ-123 | 1069 | Standard Error 38 | dyn*sec/cm^5 |
| Systemic Vascular Resistance (SVR) | BQ-123 | Time 5: Hypoxia/BQ-123 | 828 | Standard Error 43 | dyn*sec/cm^5 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | BQ-123 | 38 | |
| Overall Study | COMPLETED | BQ-123 | 19 | |
| Overall Study | NOT COMPLETED | BQ-123 | 19 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | BQ-123 | ||
| Total, other adverse events | BQ-123 | 0 | 38 |
| Total, serious adverse events | BQ-123 | 0 | 38 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00759408
GET https://conductscience.org/api/trials/v1/NCT00759408/registered